Bromantane (Ladasten)

Verified against PubChem PUG REST, CID 4660557 — returned formula C16H20BrN, MW 306.24, IUPAC name N-(4-bromophenyl)adamantan-2-amine, InChIKey LWJALJDRFBXHKX-UHFFFAOYSA-N, CAS 87913-26-6, UNII N1ILS53XWK; ChEMBL4303520. WADA status verified by extracting text from the WADA Prohibited List 2026 PDF directly. Fields marked “not verified” are ones we could not confirm against a primary chemical database — we leave them blank rather than guess.

Identity, and the detail most summaries get wrong

PubChem CID 4660557 resolves bromantane as N-(4-bromophenyl)adamantan-2-amine, CAS 87913-26-6, molecular formula C16H20BrN, molecular weight 306.24 g/mol, InChIKey LWJALJDRFBXHKX-UHFFFAOYSA-N, UNII N1ILS53XWK, ChEMBL4303520. It is a small molecule, not a peptide.

The structurally important detail is the position of attachment. The amine sits at the 2-position of the adamantane cage, not the 1-position — the compound is an adamantan-2-amine, which the original pharmacology papers reflect by naming it N-(2-adamantyl)-N-(para-bromophenyl)-amine. Amantadine and memantine, the adamantanes most readers will recognise, are 1-substituted. This is not pedantry: adamantane regiochemistry changes the three-dimensional shape and the pharmacology, and bromantane does not share the NMDA-antagonist or antiviral profile of its 1-substituted relatives.

The compound was developed at the Zakusov State Institute of Pharmacology in the USSR during the 1980s and later marketed in Russia under the brand name Ladasten. Both names appear in the literature and, as with many compounds of Soviet origin, the split is close to a language split: English-language papers tend to use bromantane, Russian-language clinical papers tend to use Ladasten. It holds no approval from the FDA or EMA.

A dopaminergic mechanism that works through transcription

The best-documented mechanistic finding comes from Mikhaylova and colleagues, working in male Wistar rats given a single 50 mg/kg oral dose (PMID 17854844). They reported differential regulation of tyrosine hydroxylase — the rate-limiting enzyme in catecholamine synthesis — at both mRNA and protein level, alongside changes in dopamine and L-DOPA content, measured across the ventral tegmental area, nucleus accumbens, hypothalamus, striatum and hippocampus.

The word doing the work is differential. The reported pattern was not a uniform increase across the brain but region-specific regulation, which is why the compound is described in the literature as a modulator rather than a stimulant in the conventional sense. Acting on the synthesis enzyme rather than on the transporter is a genuinely different mechanism from that of amphetamine or methylphenidate.

The same paper reported an electrophysiological finding in hippocampal slices: at 10 µM, short-term potentiation was converted into a longer-lasting form. This reinforcement was blocked by the protein-synthesis inhibitor anisomycin and attenuated by the D1/D5 antagonist SCH23390, which places the effect downstream of both new protein synthesis and dopamine receptor signalling.

An earlier neurotoxicology screen by Iezhitsa and colleagues attributed the behavioural profile to central dopaminergic stimulation with suppression of muscarinic and nicotinic cholinergic signalling (PMID 12124651).

The epigenetic layer

Consistent with a transcriptional route, Salimgareeva and colleagues examined chromatin-modifying activity after a single 50 mg/kg intragastric dose in rats (PMID 22235395). They reported reduced histone deacetylase 1 in striatum and hippocampus, and modified levels of acetylated histone H3 at lysine 9 and histone H4 at lysine 8 across striatum, hippocampus and hypothalamus. Reducing a deacetylase generally shifts chromatin toward a more transcriptionally permissive state, which is at least directionally compatible with the reported changes in tyrosine hydroxylase expression.

Yamidanov and colleagues took a broader approach, using two-dimensional electrophoresis and mass spectrometry to survey rat brain protein expression after a single 50 mg/kg dose, and identified 13 proteins with altered expression levels (PMID 21165444).

What has not been established is the connection between these observations. No retrieved primary source demonstrates that the histone changes cause the tyrosine hydroxylase changes, and no upstream molecular target — a receptor, an enzyme, a binding partner that the compound engages first — has been identified in the primary literature. The mechanism is therefore better described as a documented sequence of downstream effects than as a mechanism in the strict sense. Review-level sources additionally describe GABAergic and serotonergic contributions and antiradical properties (PMID 24009833), but at review rather than primary level.

The human record, and what kind of evidence it is

Human data exists, which distinguishes bromantane from most compounds discussed in this category, but its character needs stating precisely. Siuniakov and colleagues published a pilot clinical trial of Ladasten in patients with psychogenic asthenic disorder, indexed by PubMed as a phase II clinical trial, reporting a combination of stimulant and anxiolytic effects (PMID 16995430). Neznamov and colleagues published an analysis in patients with neurasthenia, indexed as a randomised controlled trial, examining how subjective self-assessment of drug and placebo effects varied with EEG alpha-rhythm type and personality measures (PMID 22834121).

Four constraints apply. All are published in Russian in Eksperimental'naia i klinicheskaia farmakologiia, with only English abstracts indexed, so the methods cannot be examined from the indexed record. None reports a sample size in its indexed abstract. None appears in ClinicalTrials.gov — a registry search for bromantane and ladasten returned zero records. And none has been replicated by any group outside Russia.

The Neznamov paper is the more instructive of the two precisely because of what it studied. Its subject is the gap between subjective and objective assessment, and it reports that both drug and placebo were rated more favourably by one patient subgroup than another. A trial designed around the size of the placebo response is a signal about how much of the reported effect is attributable to expectation.

Toxicology, and an inverted dose-response

The most useful toxicology in the retrieved record is Iezhitsa and colleagues' multi-test neurological screen in rats, which is worth reading for its shape rather than any single number (PMID 12124651). Behavioural activity was stimulated across 30–300 mg/kg and suppressed across 600–9,600 mg/kg. Spontaneous motor activity rose at 30–300 mg/kg, was unchanged at 600 mg/kg, and was inhibited above it.

Pain sensitivity moved in both directions depending on dose: threshold reduced at 300–600 mg/kg, elevated above 600 mg/kg. Mydriasis occurred at every dose studied. Above 5 g/kg the animals showed increased respiration rate and depth; above 10 g/kg, blepharoptosis. Rectal temperature fell by 0.5–1 °C after virtually every dose tested.

The authors' own interpretation is the important part: they attributed the effects at lower doses to catecholaminergic action and the effects at higher doses to cholinergic action, meaning the compound does not simply become more of itself as exposure rises — it changes which system dominates. A companion acute toxicity study reached the same conclusion, that catecholaminergic effects account for action at lower doses while cholinergic effects determine action at toxic doses (PMID 10763112). A non-monotonic dose-response of this kind means findings from one exposure range cannot be extrapolated to another in either direction.

Anti-doping status

Bromantane entered general awareness through sport. Several athletes were disqualified at the 1996 Atlanta Olympic Games after the compound was detected in their samples, and Burnat and colleagues published a short report in The Lancet the following year describing it as a new doping agent (PMID 9314900).

Its current status was verified directly against the primary document rather than a secondary summary. In the World Anti-Doping Agency Prohibited List 2026, 'Bromantan' appears by name in the S6 Stimulants section, which is prohibited in-competition. The list states that all prohibited substances in the stimulants class are Specified Substances except those in S6.A, which are non-Specified Substances; bromantan is among the named entries in that section.

The distinction carries practical weight in anti-doping proceedings, because the Specified/non-Specified division affects how an adverse finding is handled and what latitude exists for reduced sanctions. Anyone subject to anti-doping jurisdiction should treat this as a current prohibition rather than a historical footnote. Detection is also unusually persistent: hydroxylated metabolites have been described in urine well beyond the point at which the parent compound has cleared, though the specific detection-window figures in circulation could not be traced to a primary source during verification.

What is not known

No human pharmacokinetic study of bromantane was located, so human absorption, half-life, bioavailability, clearance and interactions are all unmeasured in the retrievable record. The human clinical evidence consists of a small number of Russian-language papers from a single institutional lineage, published only with English abstracts, reporting no sample sizes in those abstracts, registered in no trial registry, and never replicated by a group outside Russia — and one of them is explicitly a study of how much of the response is subjective. Nothing has been tested regarding repeated or prolonged administration in any species: no tolerance study, no dependence study, no withdrawal study, and no examination of dopamine receptor regulation after chronic exposure. The upstream molecular target remains unidentified, so the mechanism is a chain of observed downstream effects rather than a described interaction. The rodent dose-response is non-monotonic, with catecholaminergic effects dominating at lower doses and cholinergic effects at higher ones, which means findings at one exposure cannot be extrapolated to another. No reproductive, developmental or carcinogenicity toxicology was found. The compound holds no FDA or EMA approval, and its legal and scheduling status varies by jurisdiction and was not established here.

Questions